广誉远：关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划

证券之星06-11 16:06

证券之星消息，广誉远(600771)06月11日在投资者关系平台上答复投资者关心的问题。

投资者提问：截至 2026.6.8，A 股重点中药上市企业（龙头/市值百亿以上）的平均PE(TTM）约20–25倍,广誉远正在脱离成长股的估值向着行业合理估值靠近，就算按照今年1亿净利润来看，给到的估值也是极其低的。当下唯一能看到公司产品里面可能会有爆发性的就只有保健酒，只有保健酒的爆发还能让广誉远维持住当下的估值，否则必将回归行业均值，尤其是大家诟病的要定增注入农业资产必将让广誉远滑入估值的深渊再无出头之日，请公司领导知悉并重视

广誉远回复：您好，感谢您的关注。关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划。未来若涉及资本运作事项，将严格按规定履行信息披露义务。

本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2642407894?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-11 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642407894","market":"sh","top_or_hot":-1,"title":"广誉远：关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/600771\">广誉远</a>(600771)06月11日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：截至 2026.6.8，A 股重点中药上市企业（龙头/市值百亿以上）的平均PE(TTM）约20–25倍,广誉远正在脱离成长股的估值向着行业合理估值靠近，就算按照今年1亿净利润来看，给到的估值也是极其低的。当下唯一能看到公司产品里面可能会有爆发性的就只有保健酒，只有保健酒的爆发还能让广誉远维持住当下的估值，否则必将回归行业均值，尤其是大家诟病的要定增注入农业资产必将让广誉远滑入估值的深渊再无出头之日，请公司领导知悉并重视</p><p>广誉远回复：您好，感谢您的关注。关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划。未来若涉及资本运作事项，将严格按规定履行信息披露义务。</p><p>本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>广誉远：关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n广誉远：关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-11 16:06 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026061100024103.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，广誉远(600771)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：截至 2026.6.8，A 股重点中药上市企业（龙头/市值百亿以上）的平均PE(TTM）约20–25倍,广誉远正在脱离成长股的估值向着行业合理估值靠近，就算按照今年1亿净利润来看，给到的估值也是极其低的。当下唯一能看到公司产品里面可能会有爆发性的就只有保健酒，只有保健酒的爆发还能让广誉远维持住当下的...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026061100024103.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600771","symbol_name":"广誉远","start_time":0,"source_url":"https://stock.stockstar.com/RB2026061100024103.shtml","article_id":"2642407894","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642407894","pubTimestamp":1781165182,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，广誉远06月11日在投资者关系平台上答复投资者关心的问题。当下唯一能看到公司产品里面可能会有爆发性的就只有保健酒，只有保健酒的爆发还能让广誉远维持住当下的估值，否则必将回归行业均值，尤其是大家诟病的要定增注入农业资产必将让广誉远滑入估值的深渊再无出头之日，请公司领导知悉并重视广誉远回复：您好，感谢您的关注。关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159041":"农业","600771":"广誉远","BK0239":"医药制造","BK0188":"融资融券","BK0077":"质押式回购"},"translate_title":"Guangyuyuan: Regarding the matter of fixed injection of agricultural assets, the company has clearly clarified that it always focuses on the main responsibility and business of traditional Chinese medicine, and there is no such plan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159041":1.5,"600771":1.5},"content_text":"证券之星消息，广誉远(600771)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：截至 2026.6.8，A 股重点中药上市企业（龙头/市值百亿以上）的平均PE(TTM）约20–25倍,广誉远正在脱离成长股的估值向着行业合理估值靠近，就算按照今年1亿净利润来看，给到的估值也是极其低的。当下唯一能看到公司产品里面可能会有爆发性的就只有保健酒，只有保健酒的爆发还能让广誉远维持住当下的估值，否则必将回归行业均值，尤其是大家诟病的要定增注入农业资产必将让广誉远滑入估值的深渊再无出头之日，请公司领导知悉并重视广誉远回复：您好，感谢您的关注。关于定增注入农业资产事宜，公司已明确澄清，始终聚焦中医药主责主业，无此类计划。未来若涉及资本运作事项，将严格按规定履行信息披露义务。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642407894","isCrawlerRequest":true}